Answers are grounded in this paper and cite their sources.
Phase I trial demonstrates safety and immunogenicity of a personalized neoantigen vaccine in solid and hematologic cancers, highlighting its potential across diverse tumor types.
The PGV001 platform is feasible, safe, and immunogenic. The OpenVax pipeline predicted immunogenic neoantigens in tumors with wide-ranging mutational burdens. Data from this study prompted three additional PGV001 trials, one in newly diagnosed glioblastoma, one in urothelial cancer in combination with an ICI, and another in prostate cancer.
No takes yet. Share an insight, caveat, or question.
Saxena et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: